A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/211, 167/260
A61K 31/195 (2006.01) C07C 43/23 (2006.01) C07C 45/56 (2006.01) C07C 45/67 (2006.01) C07C 45/74 (2006.01) C07C 47/565 (2006.01) C07C 47/575 (2006.01) C07C 49/835 (2006.01) C07C 49/84 (2006.01) C07C 59/56 (2006.01) C07C 59/64 (2006.01) C07C 59/68 (2006.01) C07C 205/22 (2006.01) C07C 205/23 (2006.01) C07C 205/26 (2006.01) C07C 205/34 (2006.01) C07C 205/37 (2006.01) C07C 205/43 (2006.01) C07C 205/45 (2006.01) C07C 205/56 (2006.01) C07C 205/57 (2006.01) C07D 207/333 (2006.01) C07D 211/32 (2006.01) C07D 211/58 (
Patent
CA 1289078
ABSTRACT OF THE DISCLOSURE Disclosed and claimed is a new pharmaceutical composition for use in the treatment of Parkinson's disease, which composition comprises levodopa and optionally a peripheric decarboxylase inhibitor such as carbidopa or benzerazide, in admixture with at least one catechol derivatives of formula (I): Image (I) or a salt thereof, wherein R1 and R2 independently represent hydrogen, optionally substituted acyl or aroyl, lower alkylcarbamoyl, X represents an electronegative substituent such as halogen, nitro, cyano, aldehyde, or trifluoromethyl and R3 represents alkyl substituted by lower alkoxy lower alkoxy, carboxy lower alkyl, thio or pyrrole group, or a group selected from: (A) Image or Image wherein R4 represents cyano or acyl and R5 represents cyano, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, hydroxyalkyl, carboxyalkyl or one of the following optionally substituted groups: carbamoyl, aroyl or heteroaroyl, or R4 and R5 form together a five to seven membered, optionally substituted cycloalkanone ring; (B) (CH2)m-COR wherein m is 2-7 and R represents hydroxy, alkyl, - 2 - represents a hydroxyl group, an amino group, an oxo atom, an optionally substituted saturated or partiaily unsaturated lower hydrocarbon group being attached through an imino group or a lower alkylimino group to the rest of the molecule, or a saturated nitrogen containing heterocyclic group being attached through a nitrogen atom in the ring to the rest of the molecule; Z represents a -CO- or =C=N-(Z)p-R4 group; Z represents an oxygen atom or an imino group; the value of p is 0 or 1; and R4 represents a hydrogen atom or an optionally substituted saturated or partially unsaturated lower hydrocarbon group being optionally attached through a carbonyl group to the rest of he molecule.
552986
Backstrom Reijo
Heinola Kalevi
Honkanen Erkki
Kaakkola Seppo
Kairisalo Pekka
Orion-Yhtyma Oy
Robic
LandOfFree
Pharmaceutical composition for the treatment of parkinson's... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the treatment of parkinson's..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of parkinson's... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1244206